

TM

9:15 am	Overview of heterogeneous treatment effects: Moving from evidence-based medicine to personalized/precision medicine
---------	---

Speakers will present a conceptual view of heterogeneous treatment effects, as well as examples of clinical trials analyzed to yield more personalized treatment effect estimates. Discussion will focus on how changes in the design of clinical research might enable a better understanding of how treatment effects vary across individuals.

Moderator Harry Selker, Tufts Medical Center

Speakers:

David Kent, Tufts Medical Center

Sanjay Basu, Stanford University

Derek Angus, University of Pittsburgh

Discussants:

Sheldon Greenfield, University of California at Irvine

Bob Temple, FDA

Q&A and Open Discussion

10:45 am	Break
----------	-------

12:20 pm

Break

Participants will pick up lunch.

12:35 pm

Discussion with stakeholders

This session will focus on how representatives of several patient communities have applied research to guide their own care, given their own individual circumstances. Additional stakeholders contribute to the discussion of how to better align evidence with patient-centered care.

Moderator: Bray Patrick-Lake, Duke University

Panelists:

Thomas Concan, RAND Corporation

Seth Morgan, National Multiple Sclerosis Society Advocate, Patient Stakeholder

Christine Stake, Lehigh Children's Hospital, Patient Stakeholder

Reactors:

Robert Dubois, National Pharmaceutical Council

Karina Davidson, Columbia University

Q&A and Open Discussion – engage with other stakeholders

1:30 pm

Break

1:45 pm

From Research into Practice: Implementation and oversight

This session will focus on barriers to implementation applying predictions in clinical practice and how to overcome them. Speakers will discuss how to go beyond “all-or-nothing” quality measures to incentivize more personalized care.

Moderator: Nilay Shah, Mayo Clinic

Speakers:

John Spertus, Saint Luke's Mid America Heart Institute

Josh Peters, Vanderbilt University

Rodney Hayward, University of Michigan

Discussants:

Naomi Arons, Blue Cross Blue Shield Association

Katrina Armstrong, Massachusetts General Hospital

Q&A and Open Discussion

3:15 pm

Opportunities for collaborative action

The aim of this session is to reflect on key themes from the day's discussion, focusing on innovative methods for understanding heterogeneous treatment

Planning Committee

Thomas Concannon, PhD, MARAND Corporation  
Robert Golub, MD,